Basel Medical Group Ltd

Basel Medical Group Ltd(BMGL)股票分析

$5.190

0.000 (0.00%)收盘时

Loading chart…
最高
5.300
开盘
5.200
成交量加权均价
5.21
成交量
2.40M
市值
—
最低
5.125
成交额
12.49M
企业价值/息税折旧摊销前利润(TTM)
0.00

Basel Medical Group Ltd is a holding company, which operates through its subsidiary, Basel Medical Group Pte. Ltd. It provides a wide spectrum of general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Its orthopedic treatments and surgery include non-surgical treatments, such as medications, injections, splinting and physiotherapy, and surgical orthopedic procedures, including minimally invasive treatments for complex surgeries. Its rehabilitative therapy provides in-house physiotherapy treatments, including post-surgery rehabilitation, as well as sports therapy. Its neurosurgical care covers treatments involving spinal and brain conditions, from headaches and brain tumors to spinal issues, aneurysms and strokes. It also specializes in diagnostic imaging and outpatient care.

AI 分析 of Basel Medical Group Ltd (BMGL)

买入

Basel Medical Group Ltd (BMGL) appears to be a good buy right now, as it has shown a strong recent performance with a 5-day change of +12.31% and a 20-day change of +61.20%. The stock is currently priced at $5.11, which is significantly below its 52-week high of $18.72, indicating potential for recovery. Additionally, the RSI is at 92.981, suggesting that the stock is in a strong upward momentum. However, investors should be cautious of the high debt-to-equity ratio of 137.69%, which poses a risk to financial stability.

估值指标

Basel Medical Group Ltd(BMGL)当前预期市盈率为 0.00,5 年平均预期市盈率为 0.00。

预期市盈率

严重低估
5 年均值 P/E
0.00
当前P/E
0.00
高估
0.00
低估
0.00

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
0.00
当前EV/EBITDA
0.00
高估
0.00
低估
0.00

预期市销率

严重低估
5 年均值 P/S
0.00
当前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 对 BMGL 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BMGL

$2.44

情景价格

基

基准

基准 · 50%BMGL

$2.17

情景价格

悲

悲观

悲观 · 25%BMGL

$2.01

情景价格

事件时间线

2026-10-08 (ET)

13:30:00

Basel Medical Group Issues 6 Million Units at $1.33 Each

2026-09-16 (ET)

11:30:00

Basel Medical Group Ltd Trading Halted Due to Volatility

2026-09-15 (ET)

16:00:00

Basel Medical Group Ltd Trading Halted

2026-07-02 (ET)

14:00:00

Basel Medical Group Ltd Trading Halted

2026-03-24 (ET)

06:40:00

Basel Medical Complies with Nasdaq Periodic Filing Requirements

资讯

BMGL 常见问题 —— 由 Alphio AI 解答

Basel Medical Group Ltd is a holding company, which operates through its subsidiary, Basel Medical Group Pte. Ltd. It provides a wide spectrum of general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Its orthopedic treatments and surgery include non-surgical treatments, such as medications, injections, splinting and physiotherapy, and surgical orthopedic procedures, including minimally invasive treatments for complex surgeries. Its rehabilitative therapy provides in-house physiotherapy treatments, including post-surgery rehabilitation, as well as sports therapy. Its neurosurgical care covers treatments involving spinal and brain conditions, from headaches and brain tumors to spinal issues, aneurysms and strokes. It also specializes in diagnostic imaging and outpatient care. It operates in the Healthcare sector.

Basel Medical Group Ltd (BMGL) appears to be a good buy right now, as it has shown a strong recent performance with a 5-day change of +12.31% and a 20-day change of +61.20%. The stock is currently priced at $5.11, which is significantly below its 52-week high of $18.72, indicating potential for recovery. Additionally, the RSI is at 92.981, suggesting that the stock is in a strong upward momentum. However, investors should be cautious of the high debt-to-equity ratio of 137.69%, which poses a risk to financial stability.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易